Lecanemab and Donanemab: First Alzheimer’s Drugs to Slow Disease

Lecanemab and donanemab, two monoclonal antibodies targeting amyloid-beta plaques in the brain, have completed over a year of clinical use for early-stage Alzheimer’s disease.

While these therapies demonstrate a statistically significant slowing of cognitive decline, their long-term efficacy and the impact of recent German regulatory assessments on patient access remain under evaluation.

In clinical practice, the therapeutic goal for lecanemab and donanemab is the removal of amyloid-beta, a protein that aggregates in the brains of patients with Alzheimer’s.

During an online press conference at Neuroweek, Özgür Onur, head of the Neurological Intensive Care Unit at University Hospital Cologne, described the drugs as providing a “braking effect” on disease progression. While not a cure, the antibodies represent the first pharmacological interventions capable of influencing the underlying course of the disease.

The clinical trials established the efficacy benchmarks for these treatments. Donanemab demonstrated a 22% rate of slowing in the overall study population and 35% in patients with low-to-moderate tau pathology over 18 months.

Amyloid-related imaging abnormalities (ARIA), which can manifest as cerebral edema (swelling) or microhemorrhages (bleeding), were a primary concern during the initial regulatory approval process. However, recent observational studies indicate that these events occur less frequently than in clinical trials, likely due to stringent patient selection and rigorous MRI surveillance protocols. Because of these risks, the administration of these antibodies is restricted to specialized centers capable of managing individualized risk assessments.

Therapy 18-Month Efficacy (Slowing) Patient Population Focus
Lecanemab 27% Early-stage Alzheimer’s
Donanemab 22% (35% in low tau) Early-stage Alzheimer’s

The German Federal Joint Committee (G-BA) recently concluded that an added benefit for these therapies had “not been demonstrated,” a decision that has sparked significant debate.

The committee’s methodology, which required evaluating mild cognitive impairment separately from mild dementia and using specific comparator therapies, resulted in a smaller patient sample size, effectively diluting the measured clinical impact. While this assessment does not revoke the drugs’ market authorization, it complicates negotiations regarding reimbursement, potentially impacting long-term patient access in Germany.

Treatment with lecanemab or donanemab is not indicated for the general population or those without specific biomarker evidence of Alzheimer’s pathology. Individuals experiencing memory lapses should first undergo a comprehensive clinical evaluation at a specialized memory clinic rather than pursuing direct-to-consumer testing.

A positive biomarker result does not guarantee that an individual will develop dementia, and current medical guidelines, such as those from the DGN, do not support these tests for asymptomatic population-wide screening.

Current clinical research is shifting toward even earlier intervention. Trials such as TRAILBLAZER-ALZ 3 are investigating whether treatment can be effective in individuals who are biologically positive for Alzheimer’s markers but remain asymptomatic. Onur emphasized that future success will likely depend on a multi-modal approach rather than reliance on a single medication. “We will likely not be able to treat Alzheimer’s with a single drug,” Onur told Medscape.

  • van Dyck CH, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023.
  • Sims JR, et al. Donanemab in Early Symptomatic Alzheimer’s Disease. JAMA. 2023.
  • Sperling RA, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials. Alzheimers Dement. 2024.
  • ClinicalTrials.gov. Study of Donanemab (LY3002813) in Participants With Preclinical Alzheimer’s Disease (TRAILBLAZER-ALZ 3).
Photo of author

Priya Deshmukh - Senior Editor, Health

Priya Deshmukh Senior Editor, Health Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.

CBSA Demoting Officers Who Lost Ability to Carry Sidearm, Union Says

France Beat South Africa After Disallowed Arendse Try